Overview

This trial is active, not recruiting.

Conditions breast neoplasms, breast diseases
Treatments breast reconstruction - implant and an adm (surgimend), breast reconstruction- autologous tissue, breast reconstruction- implant + dermal sling/ld flap
Sponsor King's College London
Collaborator Guy's and St Thomas' NHS Foundation Trust
Start date July 2014
End date January 2016
Trial size 209 participants
Trial identifier NCT02557906, 153962

Summary

Some women with breast cancer have their whole breast removed as part of their treatment (mastectomy). Of these women, around 31% have more surgery to create a new breast.There are two main ways to create a new breast(i)using tissue from elsewhere on the body ("autologous" reconstruction )or (ii)using a silicone implant.

In recent years, it has been reported that by using a material called an "acellular dermal matrix" (ADM) the results of breast reconstruction surgery using an implant can be improved. ADMs are materials which originally come from animal or human skin. They act like a sling, supporting the lower part of an implant beneath the skin.

Although ADMs have been approved for used in breast reconstruction and are safe, there is very little high quality evidence to back up their reported benefits, and some studies have suggested their use may in fact increase complications.

The main purpose of this study is to find out what the actual risks and benefits of using an ADM in breast reconstruction surgery are. The investigators will follow the progress of women who have an implant based reconstruction to observe if participants develop problems; what those problems are and how participants feel about the results of their surgery. The investigators also follow the progress of women who undergo autologous reconstruction or alternative reconstructive techniques using an implant for the same reasons.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation non-randomized
Endpoint classification safety/efficacy study
Intervention model parallel assignment
Masking open label
Primary purpose treatment
Arm
(Experimental)
Breast reconstruction surgery with an implant and an ADM (Surgimend)
breast reconstruction - implant and an adm (surgimend) SurgiMend
Skin or nipple sparing mastectomy and immediate breast reconstruction with implants and SurgiMend
(Active Comparator)
Breast reconstruction surgery with autologous tissue
breast reconstruction- autologous tissue
Skin or nipple sparing mastectomy and immediate breast reconstruction with autologous tissue
(Active Comparator)
Breast reconstruction surgery using a dermal sling or a latissimus dorsi (LD)flap
breast reconstruction- implant + dermal sling/ld flap
Skin or nipple sparing mastectomy and immediate breast reconstruction using an implant and a dermal sling or a latissimus dorsi flap

Primary Outcomes

Measure
Number of patients with adverse events
time frame: 30 days
Number of patients with adverse events
time frame: 3 months
Number of patients with adverse events
time frame: 12 months

Secondary Outcomes

Measure
Aesthetic outcome measured by Photographic assessment
time frame: 12 months
BREAST-Q questionnaire score
time frame: 30 days
BREAST-Q questionnaire score
time frame: 12 months

Eligibility Criteria

Female participants at least 18 years old.

Inclusion Criteria: - Informed consent given - Unilateral or bilateral mastectomy (therapeutic, contra lateral or prophylactic) - Immediate reconstruction; - Suitable for immediate implant reconstruction with ADM Exclusion Criteria: - Patients unable to provide informed consent to participate in trial - Patients unavailable for follow-up - Not eligible for immediate breast reconstruction using an ADM

Additional Information

Official title Prospective, Multi-centre, Observational Trial Evaluating Outcomes of Immediate Breast Reconstruction Using an Implant and Acellular Dermal Matrix (SurgiMend) or Autologous Tissue
Principal investigator Michael Douek, MD FRCS
Description Despite the widespread adoption of acellular dermal matrices (ADMs) in breast reconstruction, there is limited prospective or high quality evidence on the outcomes of their use. The majority of studies on ADM are poor quality retrospective cohort studies with ill-defined, non-standardised outcome measures and heterogeneous patient populations. Recent systematic reviews have raised concerns of increased infection and seroma rates associated with ADM use which, if correct, may negate their reported advantages. Furthermore there is little high quality evidence to confirm the benefits associated with their use such as improved aesthetic outcomes. The POBRAD-M is a prospective, multicentre trial which will evaluate the early and late outcomes of immediate breast reconstruction using either an implant and ADM, autologous tissue or an alternative implant-based technique. All participants must have been deemed suitable at the outset for implant based reconstruction with an ADM irrespective of their final procedure choice. All participants will be followed up at 30 days, 3 months and 12 months to record the incidence of complications (to include implant loss, infection, seroma, haematoma and skin necrosis). Additionally Patient Reported Outcomes measures using the BREAST-Q questionnaire will be determined at 30 days and 12 months, and aesthetic outcome will be determined by panel assessment of post-operative photographs at 12 months post-operatively.
Trial information was received from ClinicalTrials.gov and was last updated in August 2016.
Information provided to ClinicalTrials.gov by King's College London.